Deucravacitinib is effective for the treatment of moderate to severe plaque PsO among patients who failed treatment with apremilast.
New Genesis is the ultimate PSO2 experience in which the time-tested elements are kept intact, while the game design, gameplay and graphics engine will be completely redesigned and reborn in all ...
Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, ...
Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
The approval was based on data from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials in adults with moderate to severe plaque psoriasis. The Food and Drug Administration (FDA) has approved Sotyktu ™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results